Skye Bioscience, Inc. (OTCQB:SKYE) has entered into an agreement with Novotech Health Holdings, a leading full-service contract research organization in Asia-Pacific, for its upcoming Phase 1 study in Australia of its SBI-100 drug candidate for the treatment of glaucoma. The San Diego, California-based biopharmaceutical company, Skye, is developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet needs.
Novotech is an internationally recognized full-service biotech specialist CRO known for its experience across the Asia-Pacific region. It will work alongside investigators of the planned study to support many aspects of the clinical trial including feasibility assessments, ethics committee and regulatory submissions, data management, statistical analysis, medical monitoring, safety services, central lab services, reporting, and project and vendor management.
